|Revision ID||Type||Time Submitted||Versioning Comment|
|54||Therapy||08/07/2017 10:33 AM||New interpretation|
Vemurafenib Dabrafenib Dabrafenib + Trametinib Vemurafenib + Cobimetinib
Johnson DB, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol 2014;32(33):3697-704
Disclaimer: You assume full responsibility for all risks associated with using this PMKB website. The IPM makes no guarantee of the comprehensiveness, reliability or accuracy of the information on this website and the IPM assumes no responsibility for errors in the information associated with this web site. Healthcare providers and patients must integrate all clinical and laboratory findings as well as information from a variety of sources before deciding on appropriate clinical care options.